CPB2102

CPB2102 is an investigational small molecule drug candidate being developed by the South Korean pharmaceutical company Corepharmbio for the treatment of cardiovascular diseases. The program is part of Corepharmbio's pipeline of incrementally modified drugs (IMDs), which focus on enhancing the delivery and patient compliance of established therapeutic agents. CPB2102 likely utilizes the company's proprietary **OD!FS (Oral Dissolving in a Few Seconds)** technology, a formulation platform that produces powders or granules designed to dissolve rapidly in the oral cavity without the need for water. This approach is intended to benefit patients with dysphagia or those requiring more convenient dosing regimens, such as the elderly population frequently treated for cardiovascular conditions. As of 2024, the specific active ingredient and clinical development phase for CPB2102 have not been publicly detailed.